文献速递肝病

非酒精性脂肪性肝病的无创评估:临床预测规则与血液生物标志物

Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
PubMed 文献 · J Hepatol · 2017-12-02

本文综述了用于识别非酒精性脂肪性肝病(NAFLD)患者中非酒精性脂肪性肝炎(NASH)和进展性纤维化风险的无创临床预测规则与血液生物标志物,包括NAFLD纤维化评分、FIB-4指数、BARD评分、角蛋白18片段、FibroTest、ELF和Pro-C3等,讨论了其优缺点及临床效用,并指出当前标志物预测可能受肝脏及肝外因素影响,尚无高度敏感和特异的检测可区分NASH与单纯性脂肪变,但联合血液标志物可提高诊断准确性。

要点

  • NAFLD纤维化评分和FIB-4指数是排除进展性纤维化的成本效益高且高度敏感的工具。
  • FibroTest或ELF等更昂贵的检测对显著和进展性纤维化的特异性更高。
  • 当前生物标志物预测可能受年龄、合并症及纤维化或NASH患病率影响。

核心结论

  • 当前生物标志物虽临床有用,但预测可能受肝脏和肝外状况影响,导致小样本患者中估计不准确。
  • 尚无高度敏感和特异的检测可区分NASH与单纯性脂肪变,但联合血液生物标志物可提高诊断准确性。

研究设计与样本

  • 综述,描述当前可用的临床预测规则和血液生物标志物,讨论其优缺点及临床效用。

主要发现

  • 当前生物标志物构成预测模型(如NAFLD纤维化评分、FIB-4指数和BARD评分)或炎症直接测量(如循环角蛋白18片段)或纤维化直接测量(如FibroTest®、ELF™或Pro-C3检测)。
  • 在临床环境中,生物标志物可区分NASH或进展性纤维化患者,预测NASH/纤维化随时间动态变化,并提供长期预后信息。
  • NAFLD纤维化评分和FIB-4指数均为成本效益高且高度敏感的工具,用于排除进展性纤维化患者,其较高评分可识别非肝脏和肝脏相关发病和死亡风险较高的患者。
  • 更昂贵的检测如FibroTest或ELF对检测显著和进展性纤维化患者更具特异性。

关键数值与推荐

  • NAFLD纤维化评分和FIB-4指数是成本效益高且高度敏感的工具,用于排除进展性纤维化患者。
  • FibroTest或ELF对检测显著和进展性纤维化患者更具特异性。

临床怎么用

  • 在临床环境中,生物标志物可用于区分NASH或进展性纤维化患者,预测NASH/纤维化随时间动态变化,并提供长期预后信息。

局限性

  • 当前生物标志物预测可能受肝脏和肝外状况(如年龄、患者合并症以及纤维化或NASH患病率)影响,可能导致小样本患者亚组中估计不准确。
  • 尚无高度敏感和特异的检测可区分NASH与单纯性脂肪变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The correct identification of patients at increased risk of non-alcoholic steatohepatitis (NASH) and advanced fibrosis is a critical step in the assessment of non-alcoholic fatty liver disease (NAFLD). Since liver biopsy is invasive, expensive and prone to sampling error, several clinical prediction rules and blood-based biomarkers have been developed as attractive and affordable alternatives for identification of patients at high risk of NASH and advanced fibrosis. Current biomarkers constitute predictive models (e.g. NAFLD fibrosis score, FIB-4 index and BARD score) or direct measures of inflammation (e.g. circulating keratin 18 fragments), or fibrosis (e.g. FibroTest®, ELF™ or Pro-C3 tests). In the clinical setting, biomarkers may discriminate between patients with NASH or advanced fibrosis, predict dynamic changes in NASH/fibrosis over time, and provide long-term prognostic information. Although clinically useful, current biomarker predictions may be influenced by hepatic and extrahepatic conditions (e.g. age, patient comorbidities, and fibrosis or NASH prevalence), which may lead to inaccurate estimates in small subsamples of patients. No highly sensitive and specific tests are available to differentiate NASH from simple steatosis. However, diagnostic accuracy can be improved by combining blood biomarkers. NAFLD fibrosis score and FIB-4 index are both cost-effective and highly sensitive tools to exclude patients with advanced fibrosis. Moreover, their higher scores may identify patients at higher risk of non-liver- and liver-related morbidity and mortality. More expensive tests such as FibroTest or ELF are more specific for detection of patients with significant and advanced fibrosis. Recent efforts have concentrated on "omics" approaches for developing and validating novel biomarkers. Herein, we describe currently available clinical prediction rules and blood-based biomarkers for identifying NASH and advanced fibrosis in patients with NAFLD, discussing their advantages and disadvantages, as well as their potential clinical utility for predicting dynamic changes over time and identifying patients at increased risk of adverse outcomes.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2017. PMID: 29154965. doi:10.1016/j.jhep.2017.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。